Peijia Medical Ltd. (HKG: 9996) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for GeminiOne, the company’s internally developed Transcatheter Edge‑to‑Edge Repair (TEER) System indicated for the treatment of mitral regurgitation.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Device registration / marketing approval |
| Product | GeminiOne Transcatheter Edge‑to‑Edge Repair (TEER) System |
| Indication | Treatment of mitral regurgitation |
| Approval Date | Announced 11 Sep 2026 (exact approval date not disclosed) |
| International Filings | EU marketing application submitted Feb 2026; US feasibility study commenced Apr 2026 |
Device Profile & Design
- Device Class: Transcatheter edge‑to‑edge repair (TEER) system – a minimally invasive interventional alternative to open‑heart surgery for mitral valve repair.
- Development: Internally developed by Peijia Medical, reflecting the company’s in‑house structural heart engineering capability.
- Structural Innovation: A unique structural design enables a smaller implant size and delivery system than conventional approaches.
- Procedural Advantage: The compact design reduces procedural complexity, a potential benefit for both operators and patients during transcatheter mitral interventions.
- Clinical Data: Trial endpoints and outcomes were not disclosed in the announcement.
Clinical & Market Context
- Disease Burden: Mitral regurgitation is among the most common valvular heart disorders, with prevalence rising sharply in aging populations; a large share of patients are deemed high‑risk or inoperable for conventional surgical repair.
- TEER Landscape: TEER has become an established transcatheter therapy for mitral regurgitation globally, and China’s structural heart device market has been expanding rapidly as domestic innovators challenge imported platforms.
- Competitive Positioning: GeminiOne’s smaller implant and delivery footprint is positioned as a key differentiator in a field where device profile and ease of use drive adoption.
Market Impact & Outlook
- China Commercialization: NMPA approval clears the path for domestic launch of GeminiOne, adding a commercial‑stage TEER asset to Peijia Medical’s structural heart portfolio.
- Global Expansion: The EU marketing submission (Feb 2026) and the US feasibility study (Apr 2026) signal an early international strategy beyond China.
- Company Trajectory: The approval reinforces Peijia Medical’s positioning as a homegrown structural heart device developer with an internally sourced innovation pipeline.
- Revenue Outlook: Launch timing, pricing, and hospital access plans were not disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for the GeminiOne TEER System. Actual results may differ due to risks including regulatory review outcomes in the EU and US, clinical performance, market adoption, reimbursement, and competitive dynamics.-Fineline Info & Tech
